Translational Bytes

May12 Treat Patients Faster: Surrogate Endpoint Use in Drug Approvals

In the recent Clinical and Translational Science perspective piece authored by Drs. Linda Jeng and Jeffrey Siegel, they illuminate a critical pathway for bringing treatments to patients faster: the use of surrogate endpoints in drug approval decisions. The authors conclude that when rigorously ...

Pharmacogenetics (PGx) is a form of precision medicine that applies knowledge of drug-gene interactions to maximize effectiveness and reduce toxicity of medications. Given the elevated risk of severe, and sometimes life-threating, chemotherapy-associated toxicities in genetically susceptible pati...

Interleukin‑6 (IL‑6) plays a central role in ulcerative colitis (UC) by activating two distinct pathways: classic signaling, mediated by the membrane‑bound IL‑6 receptor and supporting homeostasis and tissue repair, and trans‑signaling, mediated by the soluble IL‑6 receptor and driving pro‑inflamm...

Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies and demonstrated promising antitumor activity in solid tumors. Accurate characterization of CAR-T cell kinetics is essential for understanding the efficacy and safety of the...

A randomized, double-blind, placebo-controlled Phase I study in 37 healthy adults of Black African origin assessed the cardiac safety of combining pyronaridine (PYR) and piperaquine (PQP), two oral long-acting antimalarial agents with potential for monthly chemoprevention. PQP is known to produce a...

2025 was a complex and challenging year for science (and the world), but for CTS it was auspicious. 2025 by the numbers was a good one. One of our key objectives continued to be becoming a beacon for the field of translational science. Growth of CTS since we relaunched as an ASCPT journal in 20...

Indomethacin is the 10 th most commonly used medication in Neonatal Intensive Care Units (NICU) for two conditions: intraventricular hemorrhage (IVH) and patent ductus arteriosus (PDA); however, current dosing has not been evidence-based. Standard weight-based dosing often leads to unpredictable c...

The newly released Biomedical Data Translator represents a groundbreaking step forward in bridging fragmented biomedical data sources into a cohesive, user-friendly research tool. Translator integrates disparate datasets — ranging from clinical and genomic to pharmacologic and more — into a scala...

Therapeutics for B-cell non-Hodgkin lymphoma (B-NHL) have advanced over recent decades, with immunotherapies taking a central role in the evolving treatment paradigm. Bispecific antibodies (bsAbs) that engage T cells (via CD3) and malignant B cells (via CD20), including four CD20×CD3 bsAbs (mosunet...

Are you involved in drug development for therapeutic peptides—whether in DMPK, clinical pharmacology, or other related disciplines? Are you unsure of how the development program differs from your standard small molecule projects? In 2023, we published an industry position paper , which was the fir...

Page:

of 19